Givinostat

From WikiMD's WELLNESSPEDIA

Chemical structure of Givinostat

Givinostat is a histone deacetylase inhibitor (HDAC inhibitor) that has been studied for its potential therapeutic effects in various diseases, including cancer and inflammatory disorders. It is a small molecule that interferes with the function of histone deacetylases, enzymes that play a critical role in the regulation of gene expression by modifying the acetylation status of histones and other proteins.

Mechanism of Action[edit]

Givinostat exerts its effects by inhibiting the activity of histone deacetylases, leading to an accumulation of acetylated histones and other proteins. This results in changes in chromatin structure and the activation or repression of specific genes. The inhibition of HDACs by Givinostat can induce cell cycle arrest, promote apoptosis, and modulate immune responses.

Clinical Applications[edit]

Givinostat has been investigated in clinical trials for its potential use in treating various conditions:

  • Cancer: Givinostat has shown promise in the treatment of certain types of cancer, including leukemia and lymphoma. By altering gene expression, it can inhibit the proliferation of cancer cells and induce their death.
  • Inflammatory Disorders: The drug has also been studied for its effects on inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Its ability to modulate immune responses makes it a candidate for treating these conditions.

Pharmacokinetics[edit]

The pharmacokinetic profile of Givinostat involves its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug's half-life and bioavailability are important factors in determining its dosing regimen.

Side Effects[edit]

Like many HDAC inhibitors, Givinostat can cause a range of side effects. Common adverse effects include gastrointestinal disturbances, fatigue, and hematological abnormalities. Monitoring and management of these side effects are crucial during treatment.

Research and Development[edit]

Ongoing research is focused on understanding the full potential of Givinostat in various therapeutic areas. Studies are exploring its use in combination with other drugs to enhance efficacy and reduce resistance.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Givinostat&oldid=6626724"